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Review TRENDS in Genetics Vol.22 No.11The receptor tyrosine kinase RET is expressed in cell
lineages derived from the neural crest and has a key role
in regulating cell proliferation, migration, differentiation
and survival during embryogenesis. Germline and
somatic mutations in RET that produce constitutively
activated receptors cause the cancer syndrome multiple
endocrine neoplasia type 2 and several endocrine and
neural-crest-derived tumors, whereas mutations result-
ing in nonfunctional RET or lower expression of RET are
found in individuals affected with Hirschsprung disease.
This review focuses on the genetics and molecular
mechanisms underlying the different inherited human
neural-crest-related disorders in which RET dysfunction
has a crucial role and discusses RET as a potential
therapeutic target.
Introduction
The human gene RET is localized on chromosome 10
(10q11.2) and contains 21 exons [1]; alternative splicing
generates three isoforms, which contain 51 (RET51),
43 (RET43) and 9 (RET9) amino acids in the carboxyl
(C)-terminal tail [2]. RET51 and RET9 are the most
prevalent and best-characterized isoforms in vivo;
RET43 has not yet been characterized. The RET51 iso-
form shows the highest transforming and kinase activity
in vitro [3], and several observations suggest that these
isoforms have different tissue-specific effects during
embryogenesis [4]. Monoisoformic RET9 mice are viable
and normal, whereas the monoisoformic RET51 mice
(which lack RET9) have kidney hypoplasia and lack
enteric ganglia from the colon [4].
RET (Figure 1) is the receptor for members of the glial
cell-derived neurotrophic factor (GDNF) family of ligands
(GFLs): namely GDNF, Neurturin, Persephin and Artemin
[5]. To stimulate RET, these GFLs first need to form a
complex with their glycosylphosphatidylinositol (GPI)-
anchored co-receptor, a member of the GDNF receptor-a
family (GFRa1–GFRa4), after which the GFL–GFRa
complex activates RET [6,7]. The GFRs differ in their
specificity for GFLs (Figure 1).Corresponding author: Hofstra, R.M.W. (r.m.w.hofstra@medgen.umcg.nl).
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www.sciencedirect.com 0168-9525/$ – see front matter  2006 Elsevier Ltd. All rights reserveDuring embryogenesis, RET is expressed in the
developing excretory system, in all lineages of the periph-
eral nervous system, and in motor and catecholaminergic
neurons of the central nervous system [8]. In addition, RET
is also expressed in C-cells of the thyroid and tumors
originating from these cells, in medullary thyroid carcino-
mas (MTCs), and in other tumors of neural crest origin
such as pheochromocytomas and neuroblastomas [9].
The role of RET in cancers was first described when
somatic rearrangements of RET (named RET/PTC) show-
ing constitutive tyrosine kinase activity were found
in papillary thyroid carcinomas (PTCs) [10]. These
RET/PTC oncoproteins, of which over ten have been
described, are all chimeric proteins in which the amino
(N)-terminal region of different proteins is fused to the
catalytic domain of RET [11]. Subsequently, germline
mutations that give rise to constitutively activated RET
proteins were discovered as the cause of the cancer syn-
drome ‘multiple endocrine neoplasia type 2’ (MEN2) [12].
By contrast, mutations causing loss of function of the RET
protein were found to be associated with Hirschsprung
disease: a developmental disorder characterized by the
absence of enteric ganglia in the intestinal tract [13].
In this review, we focus on current concepts in the
genetics and molecular mechanisms underlying the
different inherited human neural crest disorders in which
RET dysfunction plays a crucial role, and we further
discuss new developments in which RET is a therapeutic
target.Wild-type RET activation and signaling
Wild-type RET signaling is crucial for the development of
the enteric nervous system (ENS), kidney organogenesis
and spermatogenesis [14]. Activation of the tyrosine
kinase domain of RET occurs through transient homodi-
merization induced by the formation of a macromolecular
GFL–GFRa–RET complex, which involves lipid rafts
(reviewed by Saarma [15]).
Dimerization and activation of wild-type RET result in
phosphorylation of its intracellular tyrosine residues,
which act as docking sites for various adaptor proteins
(Figure 2). For an excellent review that discusses ind. doi:10.1016/j.tig.2006.09.005
Figure 1. The RET protein, its functional domains, ligands and co-receptors. Left,
functional domains of the three RET isoforms. Right, canonical (unbroken lines)
and noncanonical (broken lines) interactions of the RET ligands GDNF, Neurturin
(NRTN), Persephin (PSPN) and Artemin (ARTN) with their GFRa co-receptors. Lipid
rafts are depicted as a purple box in the plasma membrane.
628 Review TRENDS in Genetics Vol.22 No.11detail the signaling pathways activated by the wild-type
RET receptor, we refer to Ichihara et al. [16]. GDNF-
independent activation of RET has been also observed
on binding of nerve growth factor to the receptor TRKA
[17].Figure 2. RET signaling pathways. Activation of RET leads to autophosphorylation of ty
several signaling transducers. Tyr1096 is present only in the RET51 isoform. Unbroke
functional interactions.
www.sciencedirect.comNeural crest disorders associated with RET mutations
MEN2
Germline missense mutations resulting in constitutive
activation of RET cause MEN2, a dominant inherited
cancer syndrome that affects neuroendocrine organs
[12]. Depending on the tissues affected, three different
clinical subtypes can be distinguished.
(i) Mrosine
n arrowEN2A, which is characterized by medullary thyroid
carcinoma (MTC) in all affected individuals (100%);
pheochromocytoma, a tumor of the adrenal medulla
cells (50%); and hyperparathyroidism (15–30%) [18].(ii) MEN2B, which is also characterized by MTC (100%)
and pheochromocytoma (50%); instead of hyperpar-
athyroidism, however, affected individuals develop a
more complex clinical phenotype including gang-
lioneuromas on the tongue, lips and eyelids, intestinal
ganglioneuromas, thickened cornea nerves and a
marfanoid habitus. MEN2B is considered to be the
most aggressive subtype of MEN2 with the earliest
age of onset [19].(iii) Familial MTC (FMTC), usually considered to be the
third MEN2 subtype, is characterized by the mani-
festation of only MTC in four or more members of an
affected family.Hirschsprung disease
Hirschsprung disease is a complex genetic disorder
characterized by aganglionosis of variable length of the
distal gastrointestinal tract. Genetic dissection has led to
the identification of ten genes and four loci associatedwith
Hirschsprung susceptibility [20], most of which causeresidues in the cytoplasmic tail of the receptor that act as docking sites for
s indicate a direct functional interaction; broken arrows indicate indirect
Table 1. Genes involved in (syndromic) Hirschsprung diseasea
Gene Map position Phenotype Inheritance
RET 10q11.2 Non-syndromic Dominant, incomplete penetrance
Hirschsprung-MEN2A/FMTC
GDNF 5p13 Non-syndromic Non-Mendelian
Neurturin 19p13 Non-syndromic Non-Mendelian
EDNRB 13q22 Shah–Waardenburg Recessive
Non-syndromic Dominant (de novo in 80%)
EDN3 20q13 Shah-Waardenburg Recessive
Non-syndromic Dominant, incomplete penetrance
SOX10 22q13 Shah-Waardenburg Dominant (de novo in 75%)
ECE-1 1p36 Congenital heart malformation De novo dominant
ZFHX1B 2q22 Mowat-Wilson De novo dominant
KIAA1279 10q21.3-q22.1 Goldberg-Shprintzen Recessive
PMX2b 4p12 Congenital central hypoventilation syndrome
(CCHS)
Dominant (de novo in 90%)
Unknown 3p21 Non-syndromic, S-HSCR Non-Mendelian
Unknown 9q31 Non-Syndromic, L-HSCR Dominant, incomplete penetrance
Unknown 19q12 Non-syndromic, S-HSCR Non-Mendelian
Unknown 16q23 Shah-Waardenburg Non-Mendelian
aReviewed in Ref. [20].
Review TRENDS in Genetics Vol.22 No.11 629syndromic Hirschsprung disease (Table 1). Of the genes
identified so far, RET has been shown to be the most
important.
Various RETmutations have been identified and corre-
lated with disease phenotype (Figure 3). The functional
consequences of the differentRETmutations have also been
characterized [12,21,22] (Table 2). A recent update on all
MEN2- and FMTC-associated RETmutations identified soFigure 3. Germline missense mutations in RET associated with MEN2 and Hirschsprung
mutated, the associated clinical entities, and the location of these mutations in relation
www.sciencedirect.comfar has been provided by Arighi et al. [14]. The RET
mutations associated with Hirschsprung disease can be
classified according to the dysfunctional mechanism of
action of the RET protein (Figure 4, Table 3).
Oncogenic RET activation and signaling in MEN2
Despite the clear correlation between mutations found in
MEN2 and their associated phenotypes, the moleculardisease (HSCR). Shown are the structure of the RET mRNA and protein. The codons
to the exons and structural domains are indicated.
able 2. Subdivision of RET mutationsa
Phenotype Codons mutated/position of the mutation Consequences of the mutation
MEN2 Level 1 C609, E768, L790, Y791, V804, S891 Mild activating RET mutations predisposing to FMTC
Level 2 C611, C618, C620, C634 Moderate activating RET mutations predisposing to FMTC or MEN2A
Level 3 A883, M918 Aggressive RET mutations predisposing to MEN2B
HSCR Class 1 Mutations in the extracellular domain Mutations disrupting RET maturation and/or transport to the membrane
Class 2 C609, C611, C618, C620 Moderate activating RET mutations predisposing to a combination of
Hirschsprung disease and FMTC or MEN2A
Class 3 Mutations in the catalytic domain Mutations altering the catalytic activity of RET
Class 4 Mutations surrounding residue Y1062 Mutations interfering with RET substrates binding to this tyrosine
Class 5 Mutations in regulatory sequences Changing the expression of the RET gene
utations are subdivided according to the predisposing phenotype, the position in the coding sequence and the consequences of the mutations for the encoded proteins
1–23]. The levels of the MEN2 mutations represent a scale of aggressiveness of the associated phenotype (level 1 represents the least aggressive and level 3 the most
ggressive phenotype).
630 Review TRENDS in Genetics Vol.22 No.11T
aM
[2
amechanisms that connect the mutated receptors with
their different clinical subtypes are far from understood.
Mutations affecting the extracellular cysteine-rich
domain of RET result in the replacement of a crucial
cysteine residue and the loss of an intramolecular disul-
fide bond, thereby facilitating the formation of an inter-
molecular disulfide bond between two (mutated) RET
monomers and producing a constitutively activated recep-
tor. Intracellular mutations, associated usually with
FMTC and always with MEN2B, signal independently
of GDNF as monomeric oncoproteins. These oncoproteins
show not only an altered catalytic activity but also an
altered substrate specificity because, unlike wild-type
RET, they phosphorylate substrates that are usually pre-
ferred by cytoplasmic tyrosine kinases such us SRC and
ABL [3]. It has been shown, however, that GDNF can
further enhance RET activity of most MEN2A proteins
and in MEN2B [23–25]. Furthermore, a different pattern
of RET receptor autophosphorylation has been found for
MEN2A-mutated (RET-MEN2A) and MEN2B-mutatedFigure 4. Classification of Hirschsprung-associated RET mutations. Shown are the differe
gene or protein affected, and their functional consequences. The mutations are classif
domain of RET, resulting in disturbed transport of RET to the plasma membrane. Cl
dimerization of the RET proteins and reduced expression of RET at the plasma memb
or alteration of the catalytic activity of the receptor. Class 4, mutations located at t
Class 5, mutations located in regulatory sequences (promoter and intron 1), resulting i
www.sciencedirect.com(RET-MEN2B) RET proteins [26,27]. As a consequence,
different sets of phosphotyrosine-mediated downstream
signaling pathways will be triggered by RET mutants
associated with specific disease phenotypes, which might
explain the distinct clinical features observed.
This hypothesis has been partially corroborated by
several studies over the past few years. For example,
Liu et al. [26] have shown that, as compared with wild-
type RET, RET-MEN2B mutants lack phosphorylation at
Tyr1096, directly leading to a decrease in binding of GRB2
to RET [26]. RET-MEN2B oncoproteins also trigger higher
levels of activated PI3K and its downstream signaling
molecules [24]. In addition, expression of RET/PTC2-
MEN2B, in contrast to that of wild-type RET/PTC2, results
in activation of the cytoskeleton protein Paxillin [28].
Furthermore, RET-MEN2Bmutants trigger higher activa-
tion of Jun N-terminal kinase (JNK) [29]. These data
suggest that the high levels of activated AKT and JNK
contribute to theMEN2B phenotype. Along the same lines,
phosphorylation of Tyr1062 of RET and its associationwithnt types of RET mutation associated with Hirschsprung disease, the domains of the
ied as follows. Class 1, mutations affecting coding sequences in the extracellular
ass 2, mutations affecting the cysteine-rich domain of RET, resulting in covalent
rane. Class 3, mutations targeting the kinase domain of RET, causing disruption
he C-terminal tail, affecting protein-binding sites and thus disrupting signaling.
n a decrease in RET mRNA levels.
Table 3. Biological properties of different RET mutant proteins in NIH-3T3 cells and mice







C6090Y + ++ [78]
C611Y + ++ [78]
C618Y + ++ [78]
C620R ++ ++ [78]
C630R ++ [78]
C634R +++/+++++ ++++ Calcitonin gene related
peptide/calcitonin promoter
MTC [79]
C634R Moloney murine leukemia
virus repeat
C-cell hyperplasia/MTC in 50% of
mice;
[80]





Benign neuroglial tumors [81–82]




C-cells and chromaffin cell
hyperplasia (early onset) and male
reproductive defects
[84]
MTC (in 3 out of 8)
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mutants, resulting in higher activation of the Ras/ERK and
the PI3K/AKT signaling pathways [25]. Also, interestingly,
the ligand-induced activation of AKT by wild-type
RET is dependent on the localization in lipid rafts, and
this regulatory mechanism is bypassed by RET-MEN2A
[30].
Finally,we shouldmentionSTAT3,a latent transcription
factor that is involved in the activation of many cytokine-
and growth-factor-inducible genes but that, when aber-
rantly activated, contributes to cancer development [31].
Transactivation of STAT3 by the RET-MEN2A mutant
RETC634R is required for cellular transformation in a
process that is independent of JAKs and SRC [32]. By
contrast, the FMTC-associated mutants RETY791F
and RETS891A implicate SRC and JAKs in constitutiveFigure 5. Possible mechanisms of activation of wild-type RET and MEN2-associated RET
anchor co-receptor 1 (GFRa1); RET is then recruited to form a macromolecular complex
domain that cause covalent dimerization of the (mutant) receptor. (c) Aberrant activation
oncoproteins with altered catalytic activity and altered substrate specificity that prefere
GDNF further enhances both RET-MEN2A and RET-MEN2B activity.
www.sciencedirect.comactivation of STAT3 [33]. Moreover, Yuan et al. [34] have
demonstrated thatRET-MEN2Bmutants interactwith and
activate STAT3 more strongly than do RET-MEN2A
mutants. These data support previous findings showing
that RET-MEN2B mutants are specifically associated with
SRC,ofwhichSTAT3 isoneof thebest-characterized targets
[35].Notably,wehave found thatSTAT3 is activated onlyby
gain-of-functionMEN2-associatedRETmutants, andnot by
ligand-stimulated wild-type RET (Ivan Plaza-Menacho,
unpublished). The different mechanisms of receptor activa-
tion by wild-type RET and MEN2-associated RET mutants
are shown in Figure 5.
Taken all together, these studies indicate that specific
signaling profiles are connected with specific MEN2-
associated RET mutations. A better understanding of
the molecular mechanisms underlying this cancermutations. (a) Activation of wild-type RET: the ligand (GDNF) first binds to the GPI-
receptor. (b) Constitutive activation of RET by mutations affecting the cysteine-rich
of mutations affecting the tyrosine kinase domain of RET, resulting in monomeric
ntially recognize substrates of cytoplasmic tyrosine kinases such as SRC or ABL.
632 Review TRENDS in Genetics Vol.22 No.11syndrome might ultimately help us to design new thera-
peutic strategies for this disease.
Polymorphisms and haplotypes in RET-associated
disorders
Not only do high penetrant germline RET mutations
have a key role in disease development, but also RET
polymorphisms and haplotypes, containing disease-
associated mutations, exist that are believed to be genetic
modifiers and might be associated with an increased
relative risk for the development of disorders derived from
neural crest cells. These polymorphisms might interact
with other genetic variants or with disease-associated
germline mutations, modulating the disease phenotype
or age of onset. How these polymorphisms contribute to
disease development is largely unknown, but there are
several possibilities:missense polymorphismsmight alter
the function of the protein, silent (coding) polymorphisms
might be involved in aberrant splicing, and noncoding
variants could regulate the level of expression. Because
polymorphisms are comparatively common in the popula-
tion, they could bestow amuch higher attributable risk on
the general population as compared with rare mutations
in high-penetrance disease susceptibility genes such as
RET.
MEN2 and FMTC
It has been suggested that the RET polymorphisms G691S
and S904S have a modifier effect on the age of onset of
MEN2A [36], and the same has been concluded for the
single-nucleotide polymorphism (SNP) L769L in combina-
tion with the FMTC germline mutation Y791F [37]. It has
also been proposed that the polymorphismG691Smight be
functional because it probably creates a new phosphoryla-
tion site affecting downstream signaling [36], or it might
change the secondary structure of RET [38].
Sporadic MTC
Several RET polymorphisms have been described in asso-
ciation with sporadic MTC. The SNPs S836S [39,40] and
IVS1–126G! T have been found to be overrepresented
and associated with the somatic mutation M918T; how-
ever, other studies have not confirmed this finding [37,41,
42]. A specific haplotype (the so-called ‘CGGATGCCAA
haplotype’) containing the SNPs G691S and S904S has
proved to be associated with sporadic MTC [38]. Both
G691S and S904S had been previously associated with
sporadic MTC and MEN2A [36,43].
Interestingly, SNP IVS14–24G! A, which was origin-
ally interpreted as a Hirschsprung mutation [44], has now
been observed more frequently in sporadic MTC [37].
Another study has found, however, that IVS14–24G! A
is not associated with either Hirschsprung or sporadic
MTC [45]. Finally, a haplotype with a protective effect
for sporadic MTC has been recently identified [38].
Sporadic pheochromocytoma
A low-penetrance RET haplotype comprising the wild-type
allele at IVS1–126 and IVS1–1463 and a 16-base-pair
intron-1 deletion 50 of these SNPs is strongly associated
with and overrepresented in sporadic pheochromocytomawww.sciencedirect.com[46]. The significant association between an individual’s
age of diagnosis and genotype suggests that the additive
effect of the haplotypes canmodulate the age of onset of the
disease.
In summary, several different RET polymorphisms and
haplotypes have been associated with different MEN2-
related endocrine tumors. For almost all polymorphisms
analyzed however, the data are inconsistent, most prob-
ably because of the small sample sizes analyzed. Thus, the
significance and mechanism of action of these potential
genetic modifiers remain to be demonstrated.
Hirschsprung disease
Inactivating coding sequence mutations in RET are
responsible for a dominant form of Hirschsprung disease
(with incomplete penetrance), and mutations are found in
up to 50% of the familial and 15% of the sporadic cases [47].
However, ample evidence indicates that, in addition to
coding sequence mutations, noncoding regions of the
RET gene also have a chief role in the development of this
disease.
This was concluded from association studies on Hirsch-
sprung populations living in The Netherlands, Italy,
France, Spain, USA and Hong Kong. The same disease-
associated haplotype was observed in the 50 region of the
RET locus in 56–62% individuals of European descent
(including Americans) [48–55]. The same haplotype was
also present in Asians, although at a much higher
frequency (85%) [52,54]. The common haplotype spans a
27-kb region (4 kb of the 50 UTR, exon 1, intron 1 [23 kb]
and exon 2 ofRET) and strongly indicates the existence of a
regulatory mutation or mutations located either in the
promoter region or in intron 1 of RET. In addition, most
of the individuals found to carry the Hirschsprung haplo-
type were homozygous for it. Because individuals who are
homozygous for the disease-associated haplotype have a
tenfold higher risk of developing the disease than hetero-
zygous carriers, a dose-dependent action of the unknown
mutation has been suggested [51].
Several groups have characterized candidate disease-
associated polymorphisms [49,55–57]. Two promoter SNPs,
rs10900296 and rs10900297 (also named SNP-5G > A and
SNP-1A > C, respectively), located just upstream of the
RET transcriptional start site, have been shown to reduce
RET promoter activity in luciferase reporter assays [49,55],
although others have shown that this effect is dependent on
the cell lines studied [57].
Two groups have described two closely located SNPs,
rs2435357 and rs2506004, in intron 1 as disease-causing
candidates on the basis of association studies, functional
assays and comparative genomics [52,56]. In particular,
the last approach seems to be useful for judging the func-
tional relevance of noncoding mutations, because it shows
that the two disease-causing candidates are located in
regulatory binding sites, which in turn are in regions that
are conserved among different vertebrate species. Further-
more, mutant alleles from rs2435357 and rs2506004 show
the highest associated values in affected individuals, and
Emison et al. [52] have found that the region containing
both of these SNPs reduces promoter activity in reporter
assays. In addition, Grice et al. [58] recently generated
Review TRENDS in Genetics Vol.22 No.11 633LacZ reporter mice that express the MCS+9.7 RET intron
1 region containing both rs2435357 and rs2506004 in the
context of the hsp68 promoter. Interestingly, they found
that the MCS+9.7 region drives a pattern of LacZ expres-
sion that resembles the temporal and spatial expression
of RET during embryonic development, which is a good
indication of the relevance of this particular region for
regulating RET expression. The transcription factor that
binds to the sequence studied by Grice et al. [58], however,
remains unidentified.
Nevertheless, many affected individuals do not have
any (RET) mutations. In these individuals, other disease
susceptibility factors must be present in the form of
rare noncoding RET mutations or mutations at other loci
either in coding or regulatory sequences.
RET as a central factor in Hirschsprung development
So far, almost all Hirschsprung-causing mutations are
found in genes encoding proteins involved in the RET
and endothelin receptor type B (EDNRB) signaling
pathways [20]. At first, these two signaling pathways
seemed to be completely unrelated. Now, however, growing
evidence indicates that these two key signal transduction
routes interact directly in the development of the ENS, at
both the genetic and the biochemical level [53,59,60]. In a
population of Old Order Mennonites, for example, it has
been shown that specific alleles of the RET and the
EDNRB loci are nonrandomly associated with Hirsch-
sprung disease and are jointly transmitted to individuals
much more often than expected [53,61].
To test the functional connection between the RET
and EDNRB pathways, McCallion et al. [59] generated
intercrossed mice from existing strains, resulting in
offspring that were compound heterozygous for a null
RET allele (truncating deletion at Lys748) and loss-of-
function EDNRB alleles (s, piebald; sl, piebald lethal)
[59]. It was thought, in particular, that the combination
of Ret and Ednrb genotypes (Ret/Ret+; Ednrbs/Ednrbs)
explained better the Hirschsprung transmission and phe-
notype observed in humans than did the independent
mutants, thereby indicating interactions between the
two pathways. McCallion et al. [59] also showed that
100% of the male offspring with this genotype were
affected; similarly, all females manifested variable length
of an aganglionic colon, although 30% had reduced clinical
expression of Hirschsprung disease, which to some extent
explains the sex bias observed in humans. Furthermore,
compound genotypes did not have strong effects on mela-
nocyte or renal development as compared with isolated
genotypes, showing that the interaction of these genes
might be specific to ENS development [59].
Work of Barlow et al. [60] in mice has elaborated on the
spatial and temporal regulation of neural crest migration
and ENS formation by the RET and EDNRB transduction
routes. Seventy per cent of double homozygotes for Ret51
andEt-3ls (the null allele of the ligand of Ednrb) developed
total intestinal aganglionosis, again indicating a strong
interaction between these two loci [62]. cAMP-dependent
protein kinase A (PKA) has been pinpointed as a likely
candidate that mediates interactions between the RET
and EDNRB pathways, because inhibition of PKAmimicswww.sciencedirect.comthe effect of ET-3 (proliferation and inhibition of
migration) on neural crest cells (NCCs) [60]. One of the
possible mechanisms of PKA action on RET signaling is
via Ser696 of RET. Phosphorylation of this residue byPKA
promotes lamellipodia formation in neuroectodermal cells
and thereby stimulates migration [63].
When the genetic and biochemical evidence is taken
together, the central role of RET in ENS development and
Hirschsprung disease is unquestionable. Nevertheless,
regulation of RET signaling by other receptors, growth
and transcription factors along the developing gut is
certainly necessary for proper development of the ENS.
Hirschsprung combined with MEN2
Mutations of extracellular residues Cys609, Cys611,
Cys618 and Cys620, which were primarily thought to be
specific for MEN2A and FMTC, have also been identified
in individualswith (sporadic)Hirschsprung disease and in
MEN2A families in which Hirschsprung sometimes seg-
regateswithMEN2AorFMTC [64]. Thesemutations have
a dual impact on RET. On the one hand, they constitu-
tively activate RET through the formation of covalent
dimers; and on the other hand, they result in a marked
reduction of RET expression at the plasma membrane.
This leads to uncontrolled proliferation of thyroid C-cells,
as seen in MEN2A and FMTC, and in apoptosis of enteric
neurons, as seen inHirschsprung disease. The reasonwhy
C-cells hyperproliferate and enteric neurons undergo
apoptosis is probably due to differences in sensitivity to
GDNF. MEN2A mutations such as C634R are responsive
to GDNF, whereas Hirschsprung–MEN2A and Hirsch-
sprung–FMTC mutations of RET (e.g. C620R) do not
respond to GDNF [65]. Insensitivity to GDNF renders
cells more prone to apoptosis, and these features are
shared by all Hirschsprung-associated mutations of
RET [66].
RET as a therapeutic target
Using drugs to target various (constitutively activated)
tyrosine kinases has been a recent success in the fight
against cancer; for example, Herceptin, Imatinib and Gefi-
tinib have been successfully used in breast cancer, gastro-
intestinal stromal tumors and non-small-cell lung cancers,
respectively [67]. This success has directed attention to
RET as a possible therapeutic target in MEN2 and FMTC
because so far no systematic treatment for individuals with
MEN2 is available [68]. All of the crucial steps in the
activation and signaling of RETmight be subject to specific
inhibitors.
The most potent therapeutic drugs are expected to come
from tyrosine kinase inhibitors. Imatinib (Glivec orGleevec)
shows inhibitory activity against RET-MEN2A and RET-
MEN2B inMTC-derived cell lines and induces degradation
of RET; however, the concentrations needed to inhibit
cellular proliferation are high [69,70]. Encouraging results
have been obtained with another tyrosine kinase inhibitor,
BAY43–9006 [71], although resistance might become a
problem, as has been previously demonstrated for RET [72].
Another elegant approach to targeting RET might be
the inhibition of RET dimer formation. The neutralizing,
nuclease-resistant D4 aptamer can bind and inhibit
634 Review TRENDS in Genetics Vol.22 No.11wild-type RET and RET-MEN2A on the cell surface [73].
The efficacy of D4 as a therapy for RET-associated tumors
remains to be established.
Another approachmight be to use SHP-1, a cytoplasmic
phosphatase that can associate with mutated RET,
thereby reducing its degree of autophosphorylation and
consequently suppressing growth-promoting signals
mediated by the RET-induced MAPK pathway [74,75].
This reduction in autophosphorylation is activated by
somatotropin release-inhibiting factor [74].
Another option that has been explored is to target
RET with monoclonal antibodies. Yano et al. [76] have
generated an antibody that can induce internalization of
RET, but its efficacy has not been demonstrated. Alter-
natively, gene therapymight become available. Inhibition
of oncogenic RET signaling by expression of a dominant-
negative RETmutant has been investigated and reviewed
by Putzer et al. [68]. Another gene therapy approach
might be the introduction of a RET-selective ribozyme
that specifically cuts mutant RET mRNA and blocks
RET-mediated cell growth and transformation [77].
In addition to the above approaches, which all focus on
RET, one might of course target downstream signaling
proteins of (mutant) RET. In summary, the RET receptor
represents a potential theraupetic target in the neuroen-
docrine tumors observed in MEN2, in which RET
dysfunction has a crucial role.
Conclusions
In conclusion, RET provides an excellent example of how
mutations, either alone or as part of a polygenic model, can
give rise to different (inherited) human diseases by alter-
ing the signaling properties and transcriptional regulation
of the protein encoded. Unraveling the genetic and mole-
cular mechanisms underlying the different RET-related
neural crest disorders not only has been a success in the
history of genetic medicine but also has helped us to
understand how these different diseases develop and
might contribute to the development of new therapeutic
strategies.
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